Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Haneen Shalabi, DO, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD, Terry J Fry, MD

Blood (2016) 128 (22): 650.

https://doi.org/10.1182/blood.V128.22.650.650

Published: 2016

Journal Articles

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Haneen Shalabi, DO, Pamela L Wolters, PhD, Staci Martin, PhD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Daniel W. Lee, III, MD, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 1625.

https://doi.org/10.1182/blood.V128.22.1625.1625

Published: 2016

Journal Articles

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terry J. Fry, MD, Maryalice Stetler-Stevenson, MD PhD, Nirali N Shah, MD, Constance M. Yuan, MD PhD, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 1324.

https://doi.org/10.1182/blood.V126.23.1324.1324

Published: 2015

Journal Articles

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Yinmeng Yang, BS, Tasha Lin, MD, Elad Jacoby, MD, Haiying Qin, MS, Elizabeth Grier Gardner, MD, Christopher Daniel Chien, PhD, Daniel W. Lee, III, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 100.

https://doi.org/10.1182/blood.V126.23.100.100

Published: 2015

Journal Articles

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

David F. Stroncek, MD, Daniel W. Lee, III, MD, Jiaqiang Ren, MD PhD, Marianna Sabatino, MD, Hanh Khuu, MD, Melinda S. Merchant, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 383.

https://doi.org/10.1182/blood.V126.23.383.383

Published: 2015

Journal Articles

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Terry J. Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 684.

https://doi.org/10.1182/blood.V126.23.684.684

Published: 2015

Journal Articles

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Daniel W. Lee, III, MD, Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, Cindy Delbrook, RN, Kelly Richards, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, M.D., Ph.D., David Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2013) 122 (21): 68.

https://doi.org/10.1182/blood.V122.21.68.68

Published: 2013

Journal Articles

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, MD, Barbara Tumaini, MS, Kelly Richards, RN, Cindy Delbrook, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, David Stroncek, MD, Crystal L Mackall, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 2609.

https://doi.org/10.1182/blood.V120.21.2609.2609

Published: 2012

Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD

Blood (2012) 120 (21): 2611.

https://doi.org/10.1182/blood.V120.21.2611.2611

Published: 2012

Journal Articles

ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo

Daniel W. Lee, III, MD, James N Kochenderfer, Rimas J Orentas, PhD, Elizabeth G. Gardner, B.S., Crystal L Mackall, MD

Blood (2011) 118 (21): 574.

https://doi.org/10.1182/blood.V118.21.574.574

Published: 2011

NARROW

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only